Larry W Green

US Patent:

6833268, Dec 21, 2004

Filed:

Jun 10, 1999

Appl. No.:

09/329582

Inventors:

Larry L. Green - San Francisco CA
Vladimir E. Ivanov - Fremont CA
C. Geoffrey Davis - Burlingame CA

Assignee:

Abgenix, Inc. - Fremont CA

International Classification:

C12N 1563

US Classification:

4353201, 435455, 435325, 536 231, 800 13, 800 18

Abstract:

The present invention provides fully human antibodies in a transgenic animal of a desired isotype in response to immunization with any virtually any desired antigen. The human immunoglobulin heavy chain transgene in the foregoing animals comprises a human constant region gene segment comprising exons encoding the desired heavy chain isotype, operably linked to switch segments from a constant region of a different heavy chain isotype, i. e. , a non-cognate switch region. Said additional constant region segment comprises a switch region and human constant region coding segment, wherein the constant region coding segment is operably linked to a switch region that it is not normally associated with, i. e. , a non-cognate switch region. In the transgenes of the invention, the non-cognate switch region may be a switch region from a different species than the constant region coding segment.

US Patent:

6924360, Aug 2, 2005

Filed:

Dec 26, 2002

Appl. No.:

10/330613

Inventors:

Larry L. Green - San Francisco CA, US
Menashe Bar-Eli - Houston TX, US

Assignee:

Abgenix, Inc. - Freemont CA

International Classification:

C07K016/00
A61K039/395

US Classification:

5303881, 53038885, 5303913, 5303917, 4241411, 4241561, 4241811, 4241831

Abstract:

The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the diagnosis and treatment of disorders associated with increased activity of MUC18, in particular, tumors, such as melanomas.

US Patent:

7049426, May 23, 2006

Filed:

Nov 30, 2001

Appl. No.:

09/999321

Inventors:

Larry L. Green - San Francisco CA, US
Vladimir E. Ivanov - Fremont CA, US
C. Geoffrey Davis - Burlingame CA, US

Assignee:

Abgenix, Inc. - Fremont CA

International Classification:

C07H 21/02
C07H 21/04
C12N 15/63
A01K 67/00

US Classification:

536 2353, 536 231, 4353201, 800 13, 800 18

Abstract:

The present invention provides fully human antibodies in a transgenic animal of a desired isotype in response to immunization with any virtually any desired antigen. The human immunoglobulin heavy chain transgene in the foregoing animals comprises a human constant region gene segment comprising exons encoding the desired heavy chain isotype, operably linked to switch segments from a constant region of a different heavy chain isotype, i. e. , a non-cognate switch region. Said additional constant region segment comprises a switch region and human constant region coding segment, wherein the constant region coding segment is operably linked to a switch region that it is not normally associated with, i. e. , a non-cognate switch region. In the transgenes of the invention, the non-cognate switch region may be a switch region from a different species than the constant region coding segment.

US Patent:

7064244, Jun 20, 2006

Filed:

Feb 19, 2002

Appl. No.:

10/078958

Inventors:

Aya Jakobovits - Menlo Park CA, US
Raju Kucherlapati - Darien CT, US
Susan Klapholz - Stanford CA, US
Michael J Mendez - El Granada CA, US
Larry Green - San Francisco CA, US

Assignee:

Abgenix, Inc. - Fremont CA

International Classification:

A01K 67/027
A01K 67/033
C12P 21/00

US Classification:

800 18, 800 13, 800 6

Abstract:

The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that include plural variable (Vand Vκ) gene regions. Advantageously, the inclusion of plural variable region genes enhances the specificity and diversity of human antibodies produced by the animal. Further, the inclusion of such regions enhances and reconstitutes B-cell development to the animals, such that the animals possess abundant mature B-cells secreting extremely high affinity antibodies.

US Patent:

7067131, Jun 27, 2006

Filed:

Dec 26, 2002

Appl. No.:

10/330530

Inventors:

Jean Gudas - Los Angeles CA, US
Larry L. Green - San Francisco CA, US
Menashe Bar-Eli - Houston TX, US

Assignee:

Abgenix, Inc. - Fremont CA

International Classification:

A61K 39/395
C07K 16/00
C12P 21/00
C12P 21/04
C12P 21/08

US Classification:

4241421, 4241301, 4241551, 4241561, 4241811, 5303871, 53038815, 53038885, 5303917, 435 696, 800 6

Abstract:

The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the diagnosis and treatment of disorders associated with increased activity of MUC18, in particular, tumors, such as melanomas.

US Patent:

7285269, Oct 23, 2007

Filed:

Dec 2, 2003

Appl. No.:

10/727155

Inventors:

John S. Babcook - Vancouver, CA
Jaspal S. Kang - Surrey, CA
Orit Foord - Foster-City CA, US
Larry Green - San Francisco CA, US
Xiao Feng - Union City CA, US
Scott Klakamp - Fremont CA, US
Mary Haak-Frendscho - Newark CA, US
Palaniswami Rathanaswami - Vancouver, CA
Craig Pigott - Cambridge, GB
Meina Liang - Danville CA, US
Kathy Manchulenko - Port Coquitlam, CA
Raffaella Faggioni - Pleasanton CA, US
Giorgio Senaldi - Dublin CA, US
Qiaojuan Jane Su - San Jose CA, US

Assignee:

Amgen Fremont, Inc. - Fremont CA

International Classification:

A61K 39/395
C07K 16/24

US Classification:

4241421, 4241831, 4241811, 4241451, 53038823, 53038873, 53038875

Abstract:

Antibodies directed to the antigen TNFα and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNFα. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.

US Patent:

7435871, Oct 14, 2008

Filed:

Nov 27, 2002

Appl. No.:

10/307231

Inventors:

Larry L. Green - San Francisco CA, US
Vladimir Ivanov - Fremont CA, US

Assignee:

Amgen Fremont Inc. - Fremont CA

International Classification:

A01K 67/027
C12P 21/08
C12N 5/06

US Classification:

800 18, 800 4, 435 7021, 435326

Abstract:

The invention relates to transgenic animals bearing one or more human λ light chain loci. The invention also relates to methods and compositions for making transgenic animals that have incorporated human λ light chain loci. The invention further relates to methods of using and compositions derived from the transgenic animals that have incorporated human λ light chain loci.

US Patent:

7547817, Jun 16, 2009

Filed:

Sep 9, 2005

Appl. No.:

11/223359

Inventors:

Larry L Green - San Francisco CA, US
Vladimir E Ivanov - Fremont CA, US
Geoffrey C Davis - Burlingame CA, US

Assignee:

Amgen Fremont Inc. - South San Francisco CA

International Classification:

A01K 67/00
A01K 67/027
C12N 15/00
C12P 21/00

US Classification:

800 18, 800 13, 800 21, 800 6

Abstract:

The present invention provides fully human antibodies in a transgenic animal of a desired isotype in response to immunization with any virtually any desired antigen. The human immunoglobulin heavy chain transgene in the foregoing animals comprises a human constant region gene segment comprising exons encoding the desired heavy chain isotype, operably linked to switch segments from a constant region of a different heavy chain isotype, i. e. , a non-cognate switch region. Said additional constant region segment comprises a switch region and human constant region coding segment, wherein the constant region coding segment is operably linked to a switch region that it is not normally associated with, i. e. , a non-cognate switch region. In the transgenes of the invention, the non-cognate switch region may be a switch region from a different species than the constant region coding segment.